文献速递慢阻肺

肺气肿的血液转录组与蛋白质组生物标志物

Blood-based Transcriptomic and Proteomic Biomarkers of Emphysema.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

研究在COPDGene训练样本2370例中通过差异基因表达、可变剪接和蛋白关联分析发现肺气肿血液组学生物标志物,并在COPDGene测试样本1016例和ECLIPSE研究526例中验证。共鉴定出3829个基因、942个异构体、260个外显子和714个蛋白与肺气肿显著相关,涉及11条生物学通路,且多数关联受BMI中介。预测模型在COPDGene和ECLIPSE中均显示合理预测性能,最佳模型联合临床、血细胞和蛋白数据,COPDGene测试集AUC为0.90(95%CI 0.85-0.90)。

要点

  • 血液转录组和蛋白质组分析揭示了肺气肿的关键生物学通路。
  • 联合临床、血细胞和蛋白数据的模型对肺气肿有良好预测性能(AUC 0.90)。

核心结论

  • 血液转录组和蛋白质组全分析揭示了肺气肿的关键生物学通路,并提升了肺气肿的预测能力。

研究设计与样本

  • 在COPDGene训练样本2370例中利用差异基因表达、可变剪接和蛋白关联分析发现肺气肿血液生物标志物。
  • 内部验证在COPDGene测试样本1016例中进行,外部验证在ECLIPSE研究526例中进行。
  • 采用弹性网络模型结合bootstrap在训练样本中依次使用临床、血细胞比例、RNA测序和蛋白质组生物标志物预测定量肺气肿。
  • 通过中介分析量化BMI对基因和蛋白与肺气肿关联的影响。

主要发现

  • 共有3829个基因、942个异构体、260个外显子和714个蛋白与肺气肿显著相关(错误发现率5%),并归纳出11条生物学通路。
  • 预测模型在COPDGene和ECLIPSE中均表现出合理的预测性能。
  • 性能最高的模型使用临床、血细胞和蛋白质数据,在COPDGene测试集中的AUC为0.90(95%CI 0.85-0.90)。

关键数值与推荐

  • 与肺气肿显著相关的组学标志物包括3829个基因、942个异构体、260个外显子和714个蛋白(错误发现率5%)。
  • 最佳预测模型(临床+血细胞+蛋白质)在COPDGene测试集的AUC为0.90(95%CI 0.85-0.90)。

临床怎么用

  • 血液转录组和蛋白质组标志物可能有助于肺气肿的早期识别和靶向治疗开发。
  • 联合临床、血细胞和蛋白质数据的预测模型可用于评估肺气肿严重程度。
  • 解读生物标志物与肺气肿关联时需考虑BMI的中介效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Emphysema is a chronic obstructive pulmonary disease phenotype with important prognostic implications. Identifying blood-based biomarkers of emphysema will facilitate early diagnosis and development of targeted therapies. Objectives: To discover blood omics biomarkers for chest computed tomography-quantified emphysema and develop predictive biomarker panels. Methods: Emphysema blood biomarker discovery was performed using differential gene expression, alternative splicing, and protein association analyses in a training sample of 2,370 COPDGene participants with available blood RNA sequencing, plasma proteomics, and clinical data. Internal validation was conducted in a COPDGene testing sample (n = 1,016), and external validation was done in the ECLIPSE study (n = 526). Because low body mass index (BMI) and emphysema often co-occur, we performed a mediation analysis to quantify the effect of BMI on gene and protein associations with emphysema. Elastic net models with bootstrapping were also developed in the training sample sequentially using clinical, blood cell proportions, RNA-sequencing, and proteomic biomarkers to predict quantitative emphysema. Model accuracy was assessed by the area under the receiver operating characteristic curves for subjects stratified into tertiles of emphysema severity. Measurements and Main Results: Totals of 3,829 genes, 942 isoforms, 260 exons, and 714 proteins were significantly associated with emphysema (false discovery rate, 5%) and yielded 11 biological pathways. Seventy-four percent of these genes and 62% of these proteins showed mediation by BMI. Our prediction models demonstrated reasonable predictive performance in both COPDGene and ECLIPSE. The highest-performing model used clinical, blood cell, and protein data (area under the receiver operating characteristic curve in COPDGene testing, 0.90; 95% confidence interval, 0.85-0.90). Conclusions: Blood transcriptome and proteome-wide analyses revealed key biological pathways of emphysema and enhanced the prediction of emphysema.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Suryadevara R, Gregory A, Lu R, et al. Blood-based Transcriptomic and Proteomic Biomarkers of Emphysema. Am J Respir Crit Care Med. 2024. PMID: 37917913. doi:10.1164/rccm.202301-0067OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。